

Oleksii Korzh

List of Publications by Citations

Source: <https://exaly.com/author-pdf/879638/oleksii-korzh-publications-by-citations.pdf>

Version: 2024-04-20

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

49
papers

13,565
citations

26
h-index

89
g-index

89
ext. papers

17,024
ext. citations

13.3
avg, IF

6.07
L-index

#	Paper	IF	Citations
49	Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease. <i>New England Journal of Medicine</i> , 2017 , 376, 1713-1722	59.2	2700
48	Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy. <i>New England Journal of Medicine</i> , 2019 , 380, 2295-2306	59.2	2060
47	Alogliptin after acute coronary syndrome in patients with type 2 diabetes. <i>New England Journal of Medicine</i> , 2013 , 369, 1327-35	59.2	1858
46	Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study. <i>Lancet, The</i> , 2010 , 376, 875-85	40	1646
45	Ivabradine for patients with stable coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a randomised, double-blind, placebo-controlled trial. <i>Lancet, The</i> , 2008 , 372, 807-16	40	775
44	Heart failure and mortality outcomes in patients with type 2 diabetes taking alogliptin versus placebo in EXAMINE: a multicentre, randomised, double-blind trial. <i>Lancet, The</i> , 2015 , 385, 2067-76	40	551
43	Tiotropium versus salmeterol for the prevention of exacerbations of COPD. <i>New England Journal of Medicine</i> , 2011 , 364, 1093-1103	59.2	499
42	Rivaroxaban for thromboprophylaxis in acutely ill medical patients. <i>New England Journal of Medicine</i> , 2013 , 368, 513-23	59.2	424
41	Patiromer in patients with kidney disease and hyperkalemia receiving RAAS inhibitors. <i>New England Journal of Medicine</i> , 2015 , 372, 211-21	59.2	376
40	Darapladib for preventing ischemic events in stable coronary heart disease. <i>New England Journal of Medicine</i> , 2014 , 370, 1702-11	59.2	363
39	Ivabradine in stable coronary artery disease without clinical heart failure. <i>New England Journal of Medicine</i> , 2014 , 371, 1091-9	59.2	315
38	Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with glimepiride: a randomized, 24-week, double-blind, placebo-controlled trial. <i>Diabetes, Obesity and Metabolism</i> , 2011 , 13, 928-38	6.7	302
37	Tiotropium Respimat inhaler and the risk of death in COPD. <i>New England Journal of Medicine</i> , 2013 , 369, 1491-501	59.2	270
36	Cardiac Myosin Activation with Omecamtiv Mecarbil in Systolic Heart Failure. <i>New England Journal of Medicine</i> , 2021 , 384, 105-116	59.2	164
35	Long-term safety and efficacy of empagliflozin, sitagliptin, and metformin: an active-controlled, parallel-group, randomized, 78-week open-label extension study in patients with type 2 diabetes. <i>Diabetes Care</i> , 2013 , 36, 4015-21	14.6	159
34	The Canagliflozin and Renal Endpoints in Diabetes with Established Nephropathy Clinical Evaluation (CREDENCE) Study Rationale, Design, and Baseline Characteristics. <i>American Journal of Nephrology</i> , 2017 , 46, 462-472	4.6	149
33	Canagliflozin and Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus and Chronic Kidney Disease in Primary and Secondary Cardiovascular Prevention Groups. <i>Circulation</i> , 2019 , 140, 739-750	16.7	140

32	Long-term safety and efficacy of benralizumab in patients with severe, uncontrolled asthma: 1-year results from the BORA phase 3 extension trial. <i>Lancet Respiratory Medicine</i> , 2019 , 7, 46-59	35.1	138
31	Inflammatory Biomarkers Interleukin-6 and C-Reactive Protein and Outcomes in Stable Coronary Heart Disease: Experiences From the STABILITY (Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy) Trial. <i>Journal of the American Heart Association</i> , 2017 , 6,	6	105
30	EU-Wide Cross-Sectional Observational Study of Lipid-Modifying Therapy Use in Secondary and Primary Care: the DA VINCI study. <i>European Journal of Preventive Cardiology</i> , 2021 , 28, 1279-1289	3.9	92
29	Beclomethasone/formoterol in the management of COPD: a randomised controlled trial. <i>Respiratory Medicine</i> , 2010 , 104, 1858-68	4.6	84
28	Clinical Efficacy and Safety of Evolocumab in High-Risk Patients Receiving a Statin: Secondary Analysis of Patients With Low LDL Cholesterol Levels and in Those Already Receiving a Maximal-Potency Statin in a Randomized Clinical Trial. <i>JAMA Cardiology</i> , 2017 , 2, 1385-1391	16.2	62
27	Renal, Cardiovascular, and Safety Outcomes of Canagliflozin by Baseline Kidney Function: A Secondary Analysis of the CREDENCE Randomized Trial. <i>Journal of the American Society of Nephrology: JASN</i> , 2020 , 31, 1128-1139	12.7	51
26	The BEAUTIFUL study: randomized trial of ivabradine in patients with stable coronary artery disease and left ventricular systolic dysfunction - baseline characteristics of the study population. <i>Cardiology</i> , 2008 , 110, 271-82	1.6	33
25	Single-pill combination of telmisartan/amlodipine in patients with severe hypertension: results from the TEAMSTA severe HTN study. <i>Journal of Clinical Hypertension</i> , 2012 , 14, 206-15	2.3	30
24	Omecamtiv mecarbil in chronic heart failure with reduced ejection fraction: GALACTIC-HF baseline characteristics and comparison with contemporary clinical trials. <i>European Journal of Heart Failure</i> , 2020 , 22, 2160-2171	12.3	24
23	IPCRG Consensus statement: tackling the smoking epidemic - practical guidance for primary care. <i>Primary Care Respiratory Journal: Journal of the General Practice Airways Group</i> , 2008 , 17, 185-93		22
22	Prediction of Residual Risk by Ceramide-Phospholipid Score in Patients With Stable Coronary Heart Disease on Optimal Medical Therapy. <i>Journal of the American Heart Association</i> , 2020 , 9, e015258	6	20
21	Angiotensin-Converting Enzyme Inhibitor Use and Major Cardiovascular Outcomes in Type 2 Diabetes Mellitus Treated With the Dipeptidyl Peptidase 4 Inhibitor Alogliptin. <i>Hypertension</i> , 2016 , 68, 606-13	8.5	18
20	Effect of SGLT2 Inhibitors on Stroke and Atrial Fibrillation in Diabetic Kidney Disease: Results From the CREDENCE Trial and Meta-Analysis. <i>Stroke</i> , 2021 , 52, 1545-1556	6.7	11
19	The impact of governance in primary health care delivery: a systems thinking approach with a European panel. <i>Health Research Policy and Systems</i> , 2019 , 17, 65	3.7	10
18	Effects of the lercanidipine-enalapril combination vs. the corresponding monotherapies on home blood pressure in hypertension: evidence from a large database. <i>Journal of Hypertension</i> , 2016 , 34, 139-48	1.9	8
17	Interleukin 6 and Cardiovascular Outcomes in Patients With Chronic Kidney Disease and Chronic Coronary Syndrome. <i>JAMA Cardiology</i> , 2021 ,	16.2	5
16	Self-Reported Health and Outcomes in Patients With Stable Coronary Heart Disease. <i>Journal of the American Heart Association</i> , 2017 , 6,	6	4
15	Diabetes mortality and trends before 25 years of age: an analysis of the Global Burden of Disease Study 2019.. <i>Lancet Diabetes and Endocrinology</i> , 2022 ,	18.1	4

14	Significance of education and self-management support for patients with chronic heart failure in family physician practice. <i>Family Medicine and Primary Care Review</i> , 2016 , 4, 432-436	0.6	3
13	The prevalence of comorbidities in COPD patients, and their impact on health status and COPD symptoms in primary care patients: a protocol for an UNLOCK study from the IPCRG. <i>Npj Primary Care Respiratory Medicine</i> , 2016 , 26, 16069	3.2	2
12	Improving the drug compliance of hypertensive patients in primary care: importance of health education and self-management. <i>Archives of the Balkan Medical Union</i> , 2019 , 54, 594-507	0.4	2
11	Cardiorenal Syndrome in Patients with Chronic Kidney Disease and Ischemic Heart Disease. <i>Polki</i> , 2016 , 45-51	0.3	2
10	CYTOKINES AS MEDIATORS OF THE IMMUNE SYSTEM AND THEIR ROLE IN THE PATHOGENESIS OF COMMUNITY-ACQUIRED PNEUMONIA. <i>World of Medicine and Biology</i> , 2021 , 17, 33	0.2	1
9	We must join forces in the battle against COPD. <i>European Respiratory Journal</i> , 2015 , 46, 1526-8	13.6	
8	Clinical and pathogenetic rationale for the prevention and treatment of obesity. <i>Shidnoevropejskij Zurnal Vnutrisnoi Ta Simejnoi Medicini</i> , 2020 , 2020, 146-152	0.1	
7	State of Connective Tissue Metabolism in Mitral Valve Prolapse in Combination with Type 1 Diabetes Mellitus. <i>Ukrainskij žurnal Medicini Biologična Sportu</i> , 2020 , 5, 189-195	0.1	
6	Self-management Education in Type 2 Diabetes in Primary Care. <i>Folia Medica</i> , 2020 , 62, 525-531	0.5	
5	Knowledge and Application of Cardiovascular Disease Prevention Guidelines among Family Physicians: A Cross-sectional Study. <i>Open Access Macedonian Journal of Medical Sciences</i> , 2020 , 9, 990-995 ¹		
4	The Prevention of Cardiovascular Diseases in Diabetes Mellitus: Role of Glycemic Control. <i>Family Medicine</i> , 2019 , 76-79	0.1	
3	Managing type 2 diabetes mellitus: Role of family physicians in successful treatment goal achievement. <i>Electronic Journal of General Medicine</i> , 2019 , 16, em146	2.1	
2	The study of fibroblast growth factor-2, sulfated glycosaminoglycans and oxyproline with mitral valve prolapse in combination with type 1 diabetes mellitus. <i>EUREKA Health Sciences</i> , 2021 , 9-15	0.1	
1	Analysis of the placebo response to the therapeutic environment. <i>IOP Conference Series: Earth and Environmental Science</i> , 635 , 012013	0.3	